<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Delalande C</dc:creator>
  <dc:creator>Awale M</dc:creator>
  <dc:creator>Rubin M</dc:creator>
  <dc:creator>Probst D</dc:creator>
  <dc:creator>Ozhathil LC</dc:creator>
  <dc:creator>Gertsch J</dc:creator>
  <dc:creator>Abriel H</dc:creator>
  <dc:creator>Reymond JL</dc:creator>
  <dc:date>2019</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">We recently reported 4-chloro-2-(2-chlorophenoxy)acetamido)benzoic acid (CBA) as the first potent inhibitor of TRPM4, a cation channel implicated in cardiac diseases and prostate cancer. Herein we report a structure-activity relationship (SAR) study of CBA resulting in two new potent analogs. To design and interpret our SAR we used interactive color-coded 3D-maps representing similarities between compounds calculated with MHFP6 (MinHash fingerprint up to six bonds), a new molecular fingerprint outperforming other fingerprints in benchmarking virtual screening studies. We further illustrate the general applicability of our method by visualizing the structural diversity of active compounds from benchmarking sets in relation to decoy molecules and to drugs. MHFP6 chemical space 3D-maps might be generally helpful in designing, interpreting and communicating the results of SAR studies. The modified WebMolCS is accessible at http://gdb.unibe.ch and the code is available at https://github.com/reymond-group/webMolCS for off-line use.</dc:description>
  <dc:identifier>https://sonar.ch/global/documents/278860</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ejmech.2019.01.048</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/30708257</dc:relation>
  <dc:source>European journal of medicinal chemistry. - 2019</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Chemical space</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Cheminformatics</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Ion channels</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Structure-activity relationships</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Virtual screening</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Benzoates</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Drug Design</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Drug Evaluation, Preclinical</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">HEK293 Cells</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Models, Molecular</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Molecular Conformation</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Structure-Activity Relationship</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">TRPM Cation Channels</dc:subject>
  <dc:title xmlns:ns15="xml" ns15:lang="en">Optimizing TRPM4 inhibitors in the MHFP6 chemical space.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
